Nuvectis Pharma (NVCT) Proxy filing summary

Executive summary

• Annual meeting scheduled for June 11, 2026, with voting open until June 10, 2026.

• Shareholders can access proxy materials online or request paper/email copies by May 28, 2026.

Voting matters and shareholder proposals

• Election of Ron Bentsur as director is up for shareholder vote.

• Ratification of Kesselman & Kesselman (PwC member) as independent auditor for fiscal year ending December 31, 2026.

• Other business may be transacted as properly brought before the meeting or any adjournment.

Audit committee and external auditor matters

• Proposal to ratify Kesselman & Kesselman as the independent registered public accounting firm for 2026.